Medical device company Zimmer Biomet (NYSE:ZBH) will be reporting earnings tomorrow before market hours. Here’s what investors should know.

Zimmer Biomet beat analysts’ revenue expectations by 1.5% last quarter, reporting revenues of $1.82 billion, up 4% year on year. It was a mixed quarter for the company, with a narrow beat of analysts’ constant currency revenue estimates but EPS in line with analysts’ estimates.

Is Zimmer Biomet a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Zimmer Biomet’s revenue to grow 3.8% year on year to $2.01 billion, slowing from the 6.3% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.29 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Zimmer Biomet has missed Wall Street’s revenue estimates three times over the last two years.

Looking at Zimmer Biomet’s peers in the healthcare equipment and supplies segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Intuitive Surgical delivered year-on-year revenue growth of 25.2%, beating analysts’ expectations by 6.5%, and Boston Scientific reported revenues up 22.4%, topping estimates by 3.3%. Intuitive Surgical traded down 4% following the results.

Read our full analysis of Intuitive Surgical’s results here and Boston Scientific’s results here.

There has been positive sentiment among investors in the healthcare equipment and supplies segment, with share prices up 2.6% on average over the last month. Zimmer Biomet is up 4.5% during the same time and is heading into earnings with an average analyst price target of $124.81 (compared to the current share price of $107.80).

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.